4
Cat No. | Product Name | Synonyms | Targets |
---|---|---|---|
T2390 | Cevimeline hydrochloride hemihydrate | AChR | |
Cevimeline hydrochloride hemihydrate is a novel muscarinic receptor agonist, used as a candidate therapeutic drug for xerostomia in Sjogren's syndrome. | |||
T13421 | (-)-Cevimeline hydrochloride hemihydrate | (-)-SNI-2011,(-)-AF102B hydrochloride hemihydrate | ALK |
Cevimeline hydrochloride hemihydrate ((-)-SNI-2011), a novel muscarinic receptor agonist, is being explored as a potential treatment for xerostomia in Sjogren's syndrome, exhibiting an IC50 value indicative of its affini... | |||
T13460 | (+)-Cevimeline hydrochloride hemihydrate | (+)-AF102B hydrochloride hemihydrate,(+)-SNI-2011 | Others |
(+)-Cevimeline hydrochloride hemihydrate ((+)-SNI-2011), a potent muscarinic receptor agonist, stands as a promising therapeutic candidate for treating xerostomia in Sjogren's syndrome. This compound has demonstrated a b... | |||
T21119 | Cevimeline | AF-102B,FKS 508,SNI 2011,HSDB 7286 | |
Cevimeline, a parasympathomimetic and muscarinic agonist, affects M1 and M3 receptors. Cevimeline has been shown to treat dry mouth and Sj gren's syndrome. It is also used to reduce Xerostomia symptoms and increase saliv... |